Press release

DSM delivers continued strong earnings and cash performance in Q3 2010

Heerlen, NL, 02 Nov 2010 07:15 CET

  • Q3 operating profit from continuing operations up 28% to €185 million (versus €144 million in Q3 2009)
  • Sales growth from continuing operations 19% compared to Q3 2009
  • Continued strong Nutrition performance drives Life Sciences results
  • Very good results for Materials Sciences
  • Cash flow from operating activities in Q3 €330 million
  • New strategy announced; DSM in motion: driving focused growth
  • Dividend increase of €0.10 to €1.30 per ordinary share proposed for 2010
  • Based on the continued positive business environment, 2010 is expected to be a strong year for DSM

Commenting on the results, Feike Sijbesma, Chairman of the DSM Managing Board, said: “I am pleased to report another strong quarter. Operating profit increased by almost 30% compared to the same period last year. Nutrition delivered a continued excellent performance, whilst Materials Sciences also posted very good results. Our strong market focus, disciplined cost and cash management and a broadly improving business environment helped drive these results. Based on the continued positive business environment we expect 2010 to be a strong year for DSM.

The announcement of our new corporate strategy – DSM in motion: driving focused growth – marks the shift from a period of intensive portfolio management to an era of maximizing sustainable, profitable growth of the ‘new’ DSM. We are committed to fully leverage the unique opportunities in Life Sciences and Materials Sciences. With our focus on high growth economies, innovation and sustainability and with our strong capital structure and leadership in biotechnology we are in an excellent position to deliver on our ambitious sales and profit targets.”

Key figures

Q3 2010 Q3 2009 +/- in € million Jan - Sep 2010 Jan - Sep 2011 +/-
      Continuing operations:      
2,154 1,816 19% Net sales 6,419 5,196 24%
288 249 16% Operating profit before depreciation & amortization (EBITDA) 937 567 65%
185 144 28% Operating profit (EBIT) 622 268 132%
137 119   Nutrition 433 384  
-6 2   Pharma -5 16  
48 45   Performance Materials 149 45  
40 21   Polymer Intermediates 137 -5  
19 7   Base Chemicals and Materials 54 -23  
-53 -50   Other activities -146 -149  
      Discontinued operations:      
58 243   Net sales 429 654  
4 34   Operating profit before depreciation & amortization (EBITDA) 51 75  
3 21   Operating profit (EBIT) 36 33  
      Total DSM:      
2,212 2,059 7% Net sales 6,848 5,850 17%
188 165 14% Operating profit (EBIT) 658 301 119%
128 100   Net profit before exceptional items 430 155  
-49 274   Net result from exceptional items -72 242  
79 374   Net profit 358 397  
      Net earnings per ordinary share in €:      
0.76 0.53   before exceptional items, continuing operations 2.44 0.80  
0.46 2.29   including exceptional items, total DSM 2.14 2.40  

You can find the press release in full, including financial statements, below.

For more information

Lieke de Jong-Tops

Senior Communications Manager
+31 45 578 2420
media.contacts@dsm.com

Dave Huizing

Vice President Investor Relations
+31 45 578 2864
investor.relations@dsm.com

Media Relations

+31 45 578 2420

Investor Relations

+31 45 578 2864

This site uses cookies to store information on your computer.

Learn more